Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ImmunoGen, Inc. IMGN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
33/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$14.79
-52.6%

ImmunoGen, Inc. (IMGN) is a Biotechnology company in the Healthcare sector, currently trading at $31.24. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is IMGN = $15 (-52.6% upside).

Financials: revenue is $109M, +23.1%/yr average growth. Net income is $223M (loss), growing at -41.2%/yr. Net profit margin is -204.9% (negative). Gross margin is 99.8% (+139 pp trend).

Balance sheet: total debt is $15M against $156M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 2.26 (strong liquidity). Debt-to-assets is 4.4%. Total assets: $349M.

Analyst outlook: 6 / 22 analysts rate IMGN as buy (27%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 16/100 (Fail), Income 10/100 (Fail).

$14.79
▼ 52.65% Downside
Average Price Target
Based on 22 Wall Street analysts offering 12-month price targets for ImmunoGen, Inc., the average price target is $14.79, with a high forecast of $22.00, and a low forecast of $6.36.
Highest Price Target
$22.00
Average Price Target
$14.79
Lowest Price Target
$6.36

IMGN SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IMGN

✗
VALUE Fail
10/100
IMGN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $15, implying -52% from the current price $31. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
IMGN: +23.1%/yr revenue is, -41.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet IMGN: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 2.26 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
IMGN: Gross margin is 99.8% (+139 pp trend), $9B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 6 / 22 analysts rate IMGN as buy (27%). Analyst consensus target is $15 (-52% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
IMGN: Net profit margin is -204.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.61-31.25
Volume19.31M
Avg Volume (30D)8.29M
Market Cap$8.73B
Beta (1Y)1.17
Share Statistics
EPS (TTM)-0.88
Shares Outstanding$253.63M
IPO Date1989-11-17
Employees277
CEOMark Joseph Enyedy
Financial Highlights & Ratios
Revenue (TTM)$108.78M
Gross Profit$108.61M
EBITDA$-220.1M
Net Income$-222.93M
Operating Income$-220.89M
Total Cash$275.14M
Total Debt$15.24M
Net Debt$-259.89M
Total Assets$348.94M
Price / Earnings (P/E)-35.5
Price / Sales (P/S)80.21
Analyst Forecast
1Y Price Target$16.00
Target High$22.00
Target Low$6.36
Upside-48.8%
Rating ConsensusHold
Analysts Covering22
Buy 27% Hold 68% Sell 5%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45253H1014

Price Chart

Track all markets on TradingView
IMGN
ImmunoGen, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.61 52WK RANGE 31.25

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+3.28%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.56
+2.28%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
 ICPT
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
+0.21%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message